We thank Hung and Chao for their interest in our work [1]. Their letter [2] allowed us to specify some relevant aspects about APULEIO (Treatment satisfaction of Italian patients undergoing Apixaban anticoagulant therapy in real-world clinical practice), a multicentre, prospective, observational study, designed to describe the psychological effects of apixaban in Italian elderly patients with atrial fibrillation (AF), deep vein thrombosis (DVT) or pulmonary embolism (PE) [1,3]. In particular, patients’ oral anticoagulant satisfaction to therapy, measured with the Anti-Clot Treatment Scale (ACTS), health-related quality of life (HRQL) and depressive symptoms had to be evaluated during a 6-month window [1,3].
